These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20421406)

  • 1. Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
    Kityo C; Walker AS; Dickinson L; Lutwama F; Kayiwa J; Ssali F; Nalumenya R; Tumukunde D; Munderi P; Reid A; Gilks CF; Gibb DM; Khoo S;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2965-73. PubMed ID: 20421406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
    Hsu A; Isaacson J; Brun S; Bernstein B; Lam W; Bertz R; Foit C; Rynkiewicz K; Richards B; King M; Rode R; Kempf DJ; Granneman GR; Sun E
    Antimicrob Agents Chemother; 2003 Jan; 47(1):350-9. PubMed ID: 12499212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
    Gupta SK; Rosenkranz SL; Cramer YS; Koletar SL; Szczech LA; Amorosa V; Hall SD
    AIDS; 2008 Oct; 22(15):1919-27. PubMed ID: 18784455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
    Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Ndagijimana J; Verweel G; Hartwig NG; Niehues T; De Groot R; Burger DM
    J Acquir Immune Defic Syndr; 2005 May; 39(1):63-8. PubMed ID: 15851915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
    Ofotokun I; Chuck SK; Binongo JN; Palau M; Lennox JL; Acosta EP
    J Clin Pharmacol; 2007 Aug; 47(8):970-7. PubMed ID: 17615254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
    Busse KH; Formentini E; Alfaro RM; Kovacs JA; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):561-6. PubMed ID: 18645517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
    Solas C; Poizot-Martin I; Drogoul MP; Ravaux I; Dhiver C; Lafeuillade A; Allegre T; Mokhtari M; Moreau J; Lepeu G; Petit N; Durand A; Lacarelle B
    Br J Clin Pharmacol; 2004 Apr; 57(4):436-40. PubMed ID: 15025741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
    Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
    King JR; Acosta EP; Yogev R; Wiznia A; Kraimer J; Graham B; Carey V; Britto P; Jean-Philippe P; Moye J; Watson D
    Pediatr Infect Dis J; 2009 Feb; 28(2):159-61. PubMed ID: 19106779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.
    Decloedt EH; McIlleron H; Smith P; Merry C; Orrell C; Maartens G
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3195-200. PubMed ID: 21537021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced lopinavir exposure during pregnancy.
    Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS
    AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
    Cressey TR; Green H; Khoo S; Treluyer JM; Compagnucci A; Saidi Y; Lallemant M; Gibb DM; Burger DM;
    Clin Infect Dis; 2008 May; 46(10):1601-8. PubMed ID: 18419497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.